Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.
about
Engineered T cells for cancer treatmentDriving CAR T-cells forwardAdoptive T-cell therapy for cancer in the United kingdom: a review of activity for the British Society of Gene and Cell Therapy annual meeting 2015.Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cellsDesign and development of therapies using chimeric antigen receptor-expressing T cellsTargeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.Adoptive immunotherapy for cancer.Genetically modified T cells to target glioblastoma.ErbB-targeted CAR T-cell immunotherapy of cancer.CAR T-cell therapy: toxicity and the relevance of preclinical models.Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells.CAR T-cell immunotherapy: The path from the by-road to the freeway?Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy.Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics.Adoptive T-Cell Therapy for Solid Tumors.Ovarian cancer immunotherapy using PD-L1 siRNA targeted delivery from folic acid-functionalized polyethylenimine: strategies to enhance T cell killing.Tumor-targeting domains for chimeric antigen receptor T cells.Engineering Chimeric Antigen Receptors.Chimeric Antigen Receptor T Cell Therapy: Challenges to Bench-to-Bedside Efficacy.CAR T-cell immunotherapy of MET-expressing malignant mesothelioma.New Approaches in CAR-T Cell Immunotherapy for Breast Cancer.'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors.Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells.VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells.Chemotherapy-induced apoptosis, autophagy and cell cycle arrest are key drivers of synergy in chemo-immunotherapy of epithelial ovarian cancer
P2860
Q33578792-19946C65-E4C9-4E93-8138-DF0CB74DEF1EQ34046505-3EB4D0BA-9DC9-4384-A56A-6F25BD58A7DAQ35641721-4334697E-35D1-45C8-9513-701A6A887637Q36470354-6EA0DA8E-ED59-4AD2-840C-C48D7BD4B495Q37418289-94D26082-E6FD-4A9C-988A-9BE1834A0ABFQ37603527-B740FF2E-773D-4AE6-B3A7-82D1F0A4501BQ38170496-8DD88C39-1F89-4C8D-97BD-D54BAEA457BBQ38178690-981D75E0-72BA-4C2F-B4E2-4DD25E78B37EQ38389298-2CDD6E32-29A2-4AD1-80C9-73CBC4F1F3BDQ38525018-07986854-FE9A-40B6-B393-70A2568FDA62Q38608986-D53DEEFF-DB86-4096-BFBA-6AA263F117F3Q38632105-B64CEA73-9670-4701-BBAB-A5389789C131Q38656009-6138D73E-B9BD-441F-B83C-B9AFFE43B136Q38741113-BBC216C3-716B-4C79-BB7B-2286E72A0DA5Q38754498-FDC8C6F3-DD72-4036-A3AE-A44966806485Q38888264-E758976F-6C8B-4066-9682-34DD40FE8653Q39045535-D86DC882-2430-46C6-ABE6-48FE5952A012Q39276909-3817FE01-4897-4890-8BAA-BAEEEFA08829Q47193084-723535DB-B575-4B19-BF6C-43009414722EQ47280088-5A5FE8EA-DBE6-4BCE-9C86-8EFEF2A4F7CFQ47761448-7AD8F9DA-B526-4466-9ECB-B83CF522834AQ47849932-1504DEDB-01E9-4EC3-B3D2-1BDADF3F6C23Q52655396-73BE97BF-27A1-46B9-A2DD-711ABBD67DCDQ55129555-4D06E2D6-B63D-4C23-B9CE-E8BC127C4883Q58703256-DFCBB4DD-470F-4502-860F-61D7E5CED630
P2860
Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Flexible targeting of ErbB dim ...... enetically engineered T cells.
@ast
Flexible targeting of ErbB dim ...... enetically engineered T cells.
@en
type
label
Flexible targeting of ErbB dim ...... enetically engineered T cells.
@ast
Flexible targeting of ErbB dim ...... enetically engineered T cells.
@en
prefLabel
Flexible targeting of ErbB dim ...... enetically engineered T cells.
@ast
Flexible targeting of ErbB dim ...... enetically engineered T cells.
@en
P2093
P2860
P50
P1433
P1476
Flexible targeting of ErbB dim ...... genetically engineered T cells
@en
P2093
Ana C Parente-Pereira
David M Davies
Julie Foster
Laura Chiapero-Stanke
Leticia Bosshard-Carter
Scott Wilkie
Sjoukje J C Van Der Stegen
Sophie E Burbridge
Stephen J Mather
Suzanne A Eccles
P2860
P2888
P304
P356
10.2119/MOLMED.2011.00493
P407
P577
2012-05-09T00:00:00Z
P5875
P6179
1068965498